Welcome to Genafor − Open Services for Medical Research

AREVIR-GenaFor-Meeting 2009

Program

Download Program (PDF)

Please visit the website, where our chairs give a summary of their sessions

Donnerstag, 23. April 2009

Zeit Vorträge

09:00 - 09:15

Begrüßung durch den Direktor des Forschungszentrum caesar, Jürgen Reifarth

09:15 - 09:30

Sicht des Patienten
Hans Thomas Sedlmayer

09:30 - 11:50

Chair: Dieter Glebe, Maria Fraune
HBV
Resistenzbestimmung, Genotypisierung, Internet tools up-date, Klinische Anwendung/Primärresistenz bei HBV, Phänotypische Resistenztestung - das Projekt HOPE, Escape-Varianten, WHO-Standards für verschiedene Genotypen, Daten verschiedener Arbeitsgruppen, Kommerzielle Assays

 

HIV-GRADE HBV-Tool
Martin Obermeier

 

Geno2pheno[HBV]
Rolf Kaiser

 

Therapy with oral antivirals in HBV infections with resistance to nucleos(t)ide analogues
Balazs Fülöp

 

Hepatitis B -- Primäre Resistenz
Andreas Erhardt

 

BMBF consortium: Hepatitis B therapies optimized by phenotypic evaluation (HOPE)
Oliver Schildgen, Hospital Mehrheim, Köln

 

Optimizing Phenotypic HBV Drug Resistance Testing for High Throughput
Ke Zhang

 

Occult hepatitis B virus infections
Dieter Glebe

 

Hepatitis-B-virus mutations in the major hydrophilic loop
Maria Fraune

 

HBV Genotype Panel
Michael Chudy

12:10 - 13:30

Chair: Lutz Gürtler, Melanie Balduin
HIV-2
Epidemiologie, Tools zur Bestimmung der Viruslast, Resistenztestung, Therapieauswahl

 

HIV-2: epidemiology, diagnosis and follow-up: the Portuguese experience
Ricardo Camacho

 

HIV-2 -- Experiences in Munich
Josef Eberle

 

HIV-2 Resistance -- Interpretation and Case Report
Martin Stürmer

 

HIV-2: From a clinical point of view
Dr. Björn Jensen

13:30 - 14:30

Mittagessen

14:30 - 15:30

Chair: Stefan Esser, Nadine Sichtig
HIV Integrase / Coronet

 

HIV-1 Integrase: not just an other HIV enzyme
Linos Vandekerckhove

 

Integrase Inhibitoren
Stefan Esser

 

Coronet -- A European Integrase Resistance Study Group

 

Evolution of raltegravir resistance during therapy
Nadine Sichtig

 

Geno2pheno[integrase]
André Altmann

15:45 - 16:45

Chair: Mark Oette
Verbund - Projekte Teil I
RKI-Serokonverter, RegaDB, RESINA, CHAIN, EuResist, Daten anderer Arbeitsgruppen

 

The German HIV-1 Seroconverter Cohort
Barbara Bartmeyer

 

RegaDB
Pieter Libin

 

ART in patients with primary HIV-resistance -- The RESINA study
Stefan Reuter

16:45 - 17:00

Kaffeepause

17:00 - 17:45

Chair: Mark Oette
The EVE study

 

The "EVE" Study
Maurizio Zazzi

 

Freitag, 24. April 2009

Zeit Vorträge

09:00 - 10:15

Chair: Herbert Pfister, Jens Verheyen
Bedeutungen der Mutationen in Gag / Protease

 

HIV can modulate Gag NC/p1 cleavage and thereby affect PI susceptibility and viral replicative capacity
Monique Nijhuis

 

Prevalence of therapy-associated HIV gag CS mutations
Jens Verheyen

 

CTL Recognition of Gag Cleavage Sites
Thomas Harrer

 

HIV-1-specific CTL and Drug Resistance
Sandra Müller, Uni Erlangen

 

A new class of drugs: maturation inhibitors -- new hope or dead end
Jens Verheyen

 

Prediction of Bevirimat Resistance in HIV-1
Dominik Heider

10:30 - 13:30

Chair: Saleta Sierra Aragon, Christoph Wyen
HIV: Coreceptor prediction update, Ultra deep sequencing

 

Clinical Use of CCR5 Antagonists
Björn Jensen

 

Genotypic prediction of viral co-receptor tropism: Correlation with enhanced Trofile
Anna Maria Geretti

 

Coreceptor Tropism of HIV-1 -- Development of a viros-free Assay
and
HIV-1 Tropism Study -- Comparison of TrofileTM and Geno2pheno[coreceptor]

Eva Heger

 

Update on geno2pheno[coreceptor]: recent integrations and results
Alexander Thielen

 

HIV tropism assessment using next generation sequencing
Mattia CF Prosperi

 

Tropism Testing with XTrackC
Heinz Stucki

 

V3 Loop Sequence Space Analysis
Kasia Bozek

 

The Berlin Maraviroc cohort -- Influence of genotypic tropism testing results on therapeutic outcome
Martin Obermeier

 

Analysis of HIV evolution in a stem cell transplanted HIV patient: indications for in silico modelling
Christel Kamp

 

Tropism, seen through the "454-loupe"
Martin Däumer

13:30 - 14:30

Mittagessen

14:30 - 16:30

Chair: Francesca Incardona, Daniel Hoffmann
Verbund / Projekte Teil II
CORUS, HIV Cell Entry / MedSys, Kompetenznetz HIV/AIDS, Assurance, HIV-Grade, Arevir

 

CORUS Project -- Coreceptor usage as a marker for specific HIV diagnostics with high sensitivity
Susanna Trapp

 

Coreceptor Usage Prediction and Model Interpretation
J. Nikolaj Dybowski

 

Comparative analysis of HIV-1 attachment and fusion efficiency
Manon Eckhardt

 

The CompNet resistance module: Current status
Klaus Jansen

 

The Role of External Quality Assessment Schemes for Laboratory Proficiency and Standardization
Hans-Peter Grunert

 

HIV GRADE Update
Hauke Walter

 

Arevir -- Analysis of resistance mutations of HI-Virus
Eugen Schülter

 

Bias-aware learning for HIV therapy screening
Jasmina Bogojeska

16:30 - 17:00

Kaffeepause

17:00 - 18:00

Chair: Thomas Lengauer, Martin Däumer
HIV and Fitness

 

Rega Institute for Medical Research
Kristof Theys

 

Viral fitness
Hauke Walter

 

Can we blame fitness for surprising therapy outcomes?
André Altmann

18:00 -

Schlusswort
Rolf Kaiser

Download Program (PDF)